reports
- Jonathan Moreland
Credit Suisse Asset Management Income Fund Inc: 1 director
A director at Credit Suisse Asset Management Income Fund Inc bought 40,766 shares at 2.920USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxvi...
TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distributor to supply TEPOXX to Japan’s national stockpileComprehensive data package demonstrates strong safety profile and robust preclinical efficacy NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, a commercial stage pharmaceutical company, announced today that its antiviral treatment TEPOXX (tecovirim...
Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of...
Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults affirm tecovirimat’s strong safety profileEfficacy in patients with more severe disease not assessed in study NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced results from an interim analy...
- Sean Conroy
SIGA Technologies - Strong order book moving into Q424
SIGA Technologies reported revenues of $10m in Q324, attributed primarily to deliveries under the $112.5m BARDA option, exercised in July 2024. Backed by a strong order book ($146m at end-Q324), the sales momentum has picked up pace in Q424 with another $51.2m and $8.5m of oral and IV TPOXX (IVT) delivered to the Strategic National Stockpile (SNS) in October 2024. We expect further deliveries in Q424 and early 2025 under the BARDA contract as well as the $9m US Department of Defense (DoD) order ...
SIGA Reports Financial Results for Three and Nine Months Ended Septemb...
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024 Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million, respectivelyReceived $122 Million of Procurement Orders from the U.S. Government in the Third QuarterCorporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2024. “Building on strong momentum,...
SIGA to Host Business Update Call on November 7 Following Release of T...
SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the I...
SIGA Enters into Exclusive License Agreement with Vanderbilt Universit...
SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (mAbs) which could be used as potential treatments for a broad range of orthopoxviruses, including smallpox and mpox. Under the agreement, SIGA has exerc...
SIGA Announces Agreement to Supply TPOXX® in Morocco
SIGA Announces Agreement to Supply TPOXX® in Morocco NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into an agreement to supply TPOXX (tecovirimat) in Morocco. The contract was executed in response to a request from the Ministry of Health in Morocco to make the therapy available in the country and help prepare and protect its citizens against any potential mpox outbreak. Tecovirimat is approved in the U.S., Canada, and the EU, and while...
- Sean Conroy
SIGA Technologies - TPOXX chalks up another DoD contract win
SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for a total of approximately $28m and adds to the already robust H224 orderbook of c $154m of outstanding TPOXX orders, following the July 2024 $112.5m option exercise from the Biomedical Advanced Research and Development Authority (BARDA) for oral TPOXX. While delivery timeline details are yet to be di...
SIGA Announces New Contract Awarded by U.S. Department of Defense for ...
SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX® NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract with the U.S. Department of Defense (DOD) for the procurement of approximately $9 million of TPOXX® (Contract number: W911SR24C0030). This award is comprised primarily of oral TPOXX®, with a small amount of intravenous (IV) TPOXX®, and represents the third procurement contract award fr...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WLDN WILLDAN GROUP
VIRC VIRCO MANUFACTURING CORP.
TBBK THE BANCORP
PSIX POWER SOLUTIONS INTERNATIONAL INC.
NWPX NORTHWEST PIPE CO.
KTOS KRATOS DEFENSE & SECURITY SOLUTIONS INC.
BFIN BANKFINANCIAL
AXGN AXOGEN INC.
ASPN ASPEN AEROGELS
MG/CN MAGNA INTERNATIONAL INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
AUP AURINIA PHARMACEUTICALS INC.
GLOB GLOBANT SA
NGS NATURAL GAS SERVICES GROUP INC.
SGMS SCIENTIFIC GAMES CORPORATION
HRB H&R BLOCK INC.
MHH MASTECH DIGITAL
KINS KINGSTONE COS. INC.
FEIM FREQUENCY ELECTRONICS INC.
SIGA SIGA TECHNOLOGIES INC.
SNFCA SECURITY NATIONAL FINANCIAL CORP. CL A
PSNL PERSONALIS
VHI VALHI INC.
KLXE KLX ENERGY SERVICES
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
CLBT CELLEBRITE DI LTD
CINT CI&T INC
RKLB ROCKET LAB USA INC
PGRU PROPERTYGURU GROUP LTD
COHR COHERENT CORP
REAX ADL VENTURES INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
FIHL FIDELIS INSURANCE HOLDINGS LIMITED
LTH LIFE TIME GROUP HLDGS INC
ANG ANGLOGOLD ASHANTI LIMITED
HG HAMILTON INSURANCE GROUP LTD.
AKA AKA BRANDS HOLDING CORP
UBXG U BX TECHNOLOGY LTD
TEM TEMPUS AI INC
BVS BAYVIEW CAPITAL TRUST I PFD 9.76%
- Sean Conroy
SIGA Technologies - PALM 007 data warrant a closer look in mpox
Although the topline results of PALM 007 (studying SIGA’s tecovirimat in the treatment of mpox) did not meet the statistical significance for the full population (primary endpoint), we are encouraged by the clinically meaningful benefit reported over placebo in early-treated patients and in those with severe disease. The data highlight an opportunity to establish an effective regime for these key populations, given the lack of effective treatment options and the overall importance of early treat...
Topline Results from PALM 007 Study of SIGA’s Tecovirimat in Treatment...
Topline Results from PALM 007 Study of SIGA’s Tecovirimat in Treatment of Mpox Released Preliminary analysis shows the study did not reach statistical significance on its primary endpoint of tecovirimat being superior to placebo in lesion resolution for all patientsResults suggest tecovirimat provides clinical benefit vs. placebo in two important patient populations: those treated early and those with severe diseaseResults affirm tecovirimat’s strong safety profileMultiple additional clinical trials evaluating tecovirimat for mpox continue NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The ...
- Sean Conroy
SIGA Technologies - Momentum building as the year progresses
SIGA Technologies had another strong quarter in Q224, driven by intravenous TPOXX (IVT) deliveries to the Strategic National Stockpile (SNS) and incremental international orders for oral TPOXX. Product revenues of $20.7m (not including the $1.1m R&D income) improved materially from $1.3m in Q223 and comprised $17.6m from IVT sales and $3.1m from international deliveries (including $2.7m under the ASEAN deal). BARDA exercising the remaining $112.5m oral TPOXX option means that top-line momentum w...
SIGA Reports Financial Results for Three and Six Months Ended June 30,...
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2024 Generated Product Sales of $21 Million in the Second Quarter, and $45 Million in the Six Months Ended June 30, 2024Received $113 Million Procurement Order from U.S. Government for Oral TPOXX in JulyCorporate Update Conference Call Today at 4:30 PM ET NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2024. “SIGA continued to perform well again this quarte...
SIGA to Host Business Update Call on August 1 Following Release of Sec...
SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 1, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Inve...
SIGA Announces U.S. Government Procurement Order of $113 Million for O...
SIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX® Exercise of Procurement Option under Current Contract Reflects Continuing Action to Enhance Orthopoxvirus Preparedness NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the U.S. Department of Health and Human Services exercised a procurement option for the delivery of approximately $113 million of oral TPOXX® treatment courses. “Building on the orders received in 2023 from the U.S. government ...
SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States
SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States Further Advances SIGA’s Strategy to Expand Access to TPOXX into More International Markets NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on global health and infectious diseases, announced today an agreement to expand access to TPOXX (tecovirimat) to the member states in the Association of Southeast Asian Nations (ASEAN), a political and economic union in the region. This agreement, which was signed by the Ministry of Health of the Government of Brunei ...
Aileron Therapeutics Reports First Quarter 2024 Financial Results and ...
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in the third quarter of 2024 AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class med...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.